Home>Topics>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Exclusive: Biogen shortens name, expands ambitions in Alzheimer's, ALS

    Headlines

    Mon, 23 Mar 2015

    NEW YORK (Reuters) - Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.

  2. UPDATE 1- Biogen's Alzheimer's drug slows mental decline in early study

    Headlines

    Fri, 20 Mar 2015

    March 20 (Reuters) - An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying

  3. Biogen's Alzheimer's drug slows mental decline in early study

    Headlines

    Fri, 20 Mar 2015

    March 20 (Reuters) - An experimental drug from Biogen Idec became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying

  4. BRIEF-Swedish Orphan Biovitrum: positive results of phase 3 clinical study of Alprolix

    Headlines

    Fri, 27 Feb 2015

    * Swedish Orphan Biovitrum and Biogen Idec announced positive results of Kids B-LONG Phase 3 clinical study that evaluated safety, efficacy and pharmacokinetics of Alprolix Source text for Eikon: Further company coverage: (Gdynia Newsroom)

  5. Raising Our Biogen Fair Value Estimate on 2015 Potential and Strengthening Pipeline

    Commentary

    Fri, 30 Jan 2015

    Biogen Idec reported 2014 results that were slightly ..... earnings per share growth this year. Overall, Biogen 's dominant position in the multiple sclerosis ..... neurology contribute to its stable wide moat. Biogen 's 2014 results were impressive, with

  6. The Top 11 Performers of 2014

    Headlines

    Tue, 20 Jan 2015

    accumulate a lot of biotech names and participate in their big runs the past couple years. Names like Amgen AMGN and Biogen Idec BIIB contributed alongside a variety of other stocks like Southwest Airlines LUV, Micron Technology MU, and Charles

  7. Nominees for 2014 Domestic-Stock Fund Manager of the Year

    Headlines

    Mon, 5 Jan 2015

    recognizes their worth, paid off in a big way in 2014. Notably, big biotech and pharmaceutical holdings--such as Biogen Idec BIIB , Amgen AMGN, Eli Lilly LLY, Roche, and Novartis NVS--in all six funds posted strong returns for the second

  8. Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

    Headlines

    Tue, 16 Dec 2014

    Name Star Rating Moat Rating Current Price (USD) Price/ FVE Fair Value Uncertainty Market Cap (USD Mil) % Stock Holdings Biogen BIIB 3 Wide 344.49 1.01 Medium 81,866 7.7 Amgen AMGN 4 Wide 164.53 0.92 Low 123,985 5.2 Eli Lilly LLY 2 Wide 69

  9. UPDATE 1- Biogen plans late-stage Alzheimer's trial, shares rise

    Headlines

    Tue, 2 Dec 2014

    Dec 2 (Reuters) - Biogen Idec Inc 's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque...

  10. Biogen plans late-stage trial for Alzheimer's treatment

    Headlines

    Tue, 2 Dec 2014

    Dec 2 (Reuters) - Biogen Idec Inc 's research chief on Tuesday said the company was planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque...

« Prev12345Next »
Content Partners